List view / Grid view
In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which new candidate medications are discovered.
Johns Hopkins University scientists have engineered a new multi-region brain organoid that mimics early human brain development. The model offers a powerful new tool for studying disorders like autism, schizophrenia and Alzheimer’s disease.
Researchers at Mount Sinai have mapped how the 5-HT1A serotonin receptor controls brain signalling – finding a hidden lipid ‘co-pilot’ that could lead to the development of more targeted antidepressants.
Japanese researchers have engineered a new lipid nanoparticle that delivers mRNA to cells five times more effectively, resulting in stronger immune responses and tumour suppression in mice.
Scientists at Ghent University have discovered that a simple combination of vitamin B1 and glucose could drastically improve survival in sepsis – a life-threatening condition responsible for millions of deaths each year.
Biomarkers aren’t just supporting drug discovery - they’re driving it. From smarter trials to faster insights, this report unpacks the science, strategy and real-world impact behind the next generation of precision therapies.
Scientists have discovered that infections like COVID-19 and flu can “wake up” dormant breast cancer cells – triggering new tumour growth in the lungs.
Cambridge researchers have discovered a new drug that could dramatically improve stroke recovery by reducing brain damage caused when blood flow is restored.
Researchers at VHIO have discovered a new way to overcome drug resistance in metastatic prostate cancer – by combining CDK4/6 inhibitors with follow-up therapies.
Scientists at Virginia Tech’s Fralin Biomedical Research Institute have identified a promising drug target – PRMT5 – that could make treatment-resistant lung, brain and pancreatic cancers more vulnerable to therapy.
Recombinant antibody technology is redefining research standards - bringing biopharma-grade precision, consistency, and customisation to the lab. Discover how advances like Fc engineering and chimerisation are accelerating progress from basic discovery to clinical insight.
Japanese researchers have discovered how the bacterial proteins FtsZ and ZapA work together to drive cell division – a discovery that could guide the development of new antibacterial treatments.
As radioligand therapy continues to show promise, its application in solid tumours remains limited by long-standing biological challenges. In this interview, Julien Torgue, CSO at Orano Med, discusses a new collaborative platform – Radio-DARPins – and how it could help overcome key barriers to clinical progress.
ELRIG (European Laboratory Research & Innovation Group) has announced the keynote speakers for Drug Discovery 2025, Europe’s premier life sciences conference, taking place at ACC Liverpool from 21–22 October 2025.
Effective financial management is vital for clinical trial success, yet many preclinical and clinical companies face inefficiencies due to outdated systems. Jennifer Kyle, CEO of Condor Software, explains how advanced financial platforms can streamline processes, improve forecasting and ensure better resource allocation throughout drug development.
Scientists have isolated a sugar molecule from deep-sea bacteria that triggers pyroptosis - a form of inflammatory cell death - to halt tumour growth - highlighting the potential of marine microbes in drug development.
